Pemvidutide (ALT-801)
ALT-801
An investigational multi-agonist being studied for obesity and metabolic liver disease.
Mechanism
Dual GLP-1 and glucagon receptor agonist
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Adults with obesity or metabolic liver disease
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Phase 2 weekly reference | 1.2, 1.8, or 2.4 mg | 1.2–2.4 mg/week | Once weekly | Same day each week | Subcutaneous | Trial-derived reference |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Arithmetic for a hypothetical 10 mg research vial only: 1.8 mg equals 0.36 mL (36 units), and 2.4 mg equals 0.48 mL (48 units). This does not reproduce a sponsor-controlled clinical-trial formulation.
Community reference: Published pemvidutide trial literatureImportant: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
No single, consistently reported subcutaneous amount-and-frequency pair is available for a responsible automatic supply calculation.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Gastrointestinal and cardiovascular observations require indication- and dose-specific interpretation.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.